ArticleJACC. Case reports2026
Transhepatic Access for Mitral Valve Replacement: Transhepatic Transseptal Mitral Valve-in-Valve.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTranscatheter mitral valve-in-valve (ViV) has emerged as a less invasive alternative to redo open surgical mitral valve replacement in patients at high surgical risk and is usually performed using a transseptal route by femoral venous access. Rarely, this approach may not be feasible owing to venous occlusions or congenital inferior vena cava (IVC) interruption. CASE SUMMARY: A patient with agenesis of the femoral vein required a mitral ViV procedure, which was successfully done using transhepatic access. DISCUSSION: Agenesis of the femoral vein is a rare malformation. The transhepatic route can be an alternative for structural procedures in these patients, albeit with technical challenges and additional risks. TAKE-HOME MESSAGES: Transhepatic access is a feasible alternative for transcatheter, transseptal procedures in patients with IVC interruption; however, special care must be taken to guarantee proper access for hemostasis. Hemorrhagic complications remain a concern in patients who undergo mitral ViV procedures owing to the need for anticoagulation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.